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Abstract
Background and Aim: Thrombocytopenia is frequently observed in patients with chronic
hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients
without cirrhosis by a virus-mediated phenomenon. This study assessed the prevalence,
characteristics, and outcomes of antiviral therapy in patients with chronic HCV infection
and thrombocytopenia not associated with cirrhosis.
Methods: The study included 1268 patients with HCV infection and thrombocyto-
penia enrolled in the phase 3 ENABLE studies that assessed the impact of eltrombopag
on achieving a sustained virologic response to pegylated interferon and ribavirin. The
study population was subdivided according to baseline FibroSURE test results into
patients with non-cirrhosis (FibroSURE < 0.4) and cirrhosis-related (FibroSURE ≥ 0.75)
thrombocytopenia.
Results: Compared with patients with cirrhosis-related thrombocytopenia (n = 995;
78.5%), non-cirrhotic patients with thrombocytopenia (n = 59; 4.6%) were younger (mean
age [95% confidence interval (CI)]: 43.9 [40.7–47.2] vs 52.7 [52.2–53.3] years;
P < 0.0001), predominantly female (64% [51–76] vs 30% [27–33]; P < 0.0001), and less
frequently had a Model for End-Stage Liver Disease score ≥ 10 (24% [14–37] vs 45%
[42–49]; P = 0.0012), low albumin levels (≤ 35 g/L; 2% [0–9] vs 32% [29–35];
P < 0.0001), and prevalence of diabetes mellitus (3% [0–12] vs 21% [19–24]; P = 0.0005).
The sustained virologic response rate was higher in non-cirrhotic patients with thrombo-
cytopenia (46% [95% CI, 33–59] vs 16% [14–18]; P < 0.0001).
Conclusions: Patients with thrombocytopenia associated with HCV who have lower
FibroSURE test results may have better preserved liver function and higher sustained
virologic response rates than patients with cirrhosis.
Introduction
Chronic hepatitis C virus (HCV) infection is associated with
various extrahepatic manifestations, including thrombocytopenia,
which is observed in approximately 25% of patients.1–3 In these
patients, thrombocytopenia has traditionally been ascribed to
platelet sequestration within the spleen due to portal hypertension
and, more recently, to decreased thrombopoietin production—both
conditions associated with advanced fibrosis and cirrhosis.4–7 No
clear correlation has been identified between platelet count and
portal pressure; however, thrombocytopenia has been observed in
HCV-infected patients without cirrhosis when other mechanisms
such as virus-induced immune-mediated platelet destruction have
been described as possible (co-)responsible factors for the
decreased platelet count.8–10
Besides representing a hallmark of advanced disease stage,
thrombocytopenia may represent an obstacle to initiation and
maintenance of pegylated interferon (PEG-IFN) and ribavirin
doi:10.1111/jgh.12942
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(RBV) therapy in patients with chronic HCV infection, and it has
been associated with an increased risk of bleeding during antiviral
treatment.11–14 However, in some cases, successful interferon anti-
viral therapy has been associated with an increase in platelet
count during treatment, and there is initial evidence that a propor-
tion of patients with HCV infection and thrombocytopenia may
display some peculiar clinical features, although the characteris-
tics and outcome of antiviral therapy according to disease stage in
these patients have not been evaluated in adequately sized
cohorts.15–17
The ENABLE-1 and ENABLE-2 (Eltrombopag to Initiate and
Maintain Interferon Antiviral Treatment to Benefit Subjects With
Hepatitis C Related Liver Disease; ClinicalTrials.gov identifiers:
NCT00516321 and NCT00529568, respectively) studies were
phase 3, randomized, placebo-controlled, multicenter trials that
enrolled a large cohort of thrombocytopenic (platelet count
< 75 × 109/L) patients with HCV infection and compensated
chronic liver disease who were otherwise good candidates for
PEG-IFN and RBV antiviral therapy. These studies demonstrated
that eltrombopag, when used as supportive treatment, increases
platelet counts to a level sufficient to initiate and maintain PEG-
IFN and significantly improves sustained virologic response
(SVR) rates to antiviral therapy as compared with placebo.18 In
these studies, severity of disease was also assessed by means of
FibroSURE (FS) testing. According to FS test results,19,20
patients were subdivided into two groups: patients with non-
cirrhotic thrombocytopenia and those with cirrhosis-related
thrombocytopenia.
This study aimed to assess the demographic, clinical, and viro-
logic characteristics, as well as the outcomes, of PEG-IFN and
RBV treatment in patients with non-cirrhotic thrombocytopenia
and chronic HCV infection and to compare these features with
those of patients with cirrhosis-related thrombocytopenia.
Methods
Patients. The ENABLE-1 and ENABLE-2 studies were con-
ducted in two sequential parts. In part 1, patients received open-
label eltrombopag until they reached the platelet count threshold
needed to initiate antiviral therapy. In part 2, patients were ran-
domized 2:1 in a double-blind fashion to receive either
eltrombopag or placebo in combination with PEG-IFN and RBV.
The primary aim of the studies was to evaluate the effect of
eltrombopag treatment on SVR. The details of each study’s inclu-
sion and exclusion criteria, as well as the characteristics of the
patient cohorts, have been described previously.18 Both ENABLE
studies were approved by the institutional review boards and/or
ethical committees, as appropriate, at each study center. This
study was conducted in accordance with Good Clinical Practice
guidelines and all applicable patient privacy requirements, and the
principles in the Declaration of Helsinki. All patients enrolled in
both studies provided written informed consent prior to study
entry.
The ENABLE studies included patients with thrombocy-
topenia and compensated chronic liver disease, and the FS test
was one of the parameters used to grade the severity of liver
disease.18,19 Baseline FS test results were available in 1268
(83.4%) of the 1521 patients enrolled in the ENABLE studies.
The FS test uses the results of six biochemical tests (alanine
aminotransferase [ALT], gamma-glutamyl transferase, haptoglo-
bin, alpha-2-macroglobulin, total bilirubin, and apolipoprotein
A1) with a patient’s age and sex to generate a measure of fibrosis
and necroinflammatory activity in the liver.20–23 FS scores corre-
late to stages of fibrosis, and a comparison of the FS test with
liver biopsy showed a negative predictive value of FS < 0.31 of
85% and a positive predictive value of 54% when analyzing a
group of 1270 HCV patients.20 In patients with chronic HCV, the
FS test results correlate with the histologic stage of liver fibrosis
expressed according to the METAVIR score.20–23 For the purpose
of this study, in line with the FS test results and the METAVIR
scoring system, we identified three groups of patients: (i)
patients with FS < 0.4, who were classified as patients with non-
cirrhotic thrombocytopenia; (ii) patients with FS ≥ 0.75, who
were classified as patients with cirrhosis-related thrombocytope-
nia; and (iii) patients with FS of 0.4 to 0.75, who cannot be
adequately classified as patients with or without cirrhosis and
were therefore not included in this analysis. Patients with FS test
results of 0.4 to 0.75 had demographic characteristics that were
similar to those of patients with cirrhosis-related thrombocyto-
penia, as shown in Table S1. For each patient, we also calculated
the Model for End-Stage Liver Disease (MELD) score and the
aspartate aminotransferase (AST)/ALT ratio as biochemical
indexes related to the severity of liver disease and the patients’
prognosis.24,25
Efficacy assessments. SVR was defined as the proportion
of patients with undetectable serum HCV RNA at 24 weeks after
completing antiviral therapy. Rapid virologic response (RVR) and
complete early virologic response (EVR) were defined as unde-
tectable serum HCV RNA at week 4 and week 12 of therapy,
respectively. EVR was defined as a decrease of 2 log10 or greater in
serum HCV RNA at week 12 as compared with baseline. End-of-
treatment response (ETR) was defined as undetectable HCV RNA
at the end of antiviral therapy (24 weeks for patients with HCV
genotypes 2 and 3; 48 weeks for patients with HCV genotype other
than 2/3).
Statistical analysis. Continuous data are shown as mean
values and 95% confidence intervals (CIs) or as median and
interquartile range; categorical data are shown as absolute count,
percentage, and 95% CI.
Results
Baseline demographic and clinical characteristics
of patients with non-cirrhotic and cirrhosis-
related thrombocytopenia. The percentage of patients
with non-cirrhotic thrombocytopenia (FS < 0.4) was 4.6%
(n = 59), while 78.5% of patients (n = 995) had cirrhosis-related
thrombocytopenia (FS ≥ 0.75), and 16.9% of patients (n = 214)
had indeterminate FS test results (FS = 0.4–0.75).
The baseline demographic, clinical, and virologic charac-
teristics of the 1054 patients with HCV infection and thrombo-
cytopenia subdivided according to FS test results are shown in
Table 1. Patients with non-cirrhotic thrombocytopenia were
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younger (mean age, 43.9 [95% CI, 40.7–47.2] vs 52.7 [52.2–53.3]
years), predominantly female (64% [51–76] vs 30% [27–33]), less
frequently had a serum albumin level below the lower limit of
normal (≤ 35 g/L; 2% [0–9] vs 32% [29–35]), an AST/ALT
ratio > 0.8 (68% [54–79] vs 90% [88–92]), prevalence of diabetes
mellitus (3% [0–12] vs 21% [19–24]), and a MELD score ≥ 10
(24% [14–37] vs 45% [42–49]).
Mean baseline platelet counts (95% CI) were 56.1 × 109/L
(51.5–60.7) and 56.7 × 109/L (55.9–57.5) in patients with non-
cirrhotic and cirrhosis-related thrombocytopenia, respectively.
Mean body mass index (26.8 kg/m2 [95% CI, 25.4–28.2] vs
27.8 kg/m2 [27.5–28.0]), virologic characteristics (genotypes 1, 4,
or 6: 71% [58–82] vs 69% [66–72]), and viral load (2.03 × 106
IU/mL [1.24–2.82] vs 1.55 × 106 IU/mL [1.39–1.70]) were similar
in patients with non-cirrhotic and cirrhosis-related thrombocyto-
penia, respectively.
Virologic response rates in patients with non-
cirrhotic and cirrhosis-related thrombocytope-
nia. Figure 1 shows the virologic response rates at key time
points during antiviral therapy in patients with non-cirrhotic and
cirrhosis-related thrombocytopenia. In particular, while RVR was
similar in the two groups (22% [95% CI, 12–35] vs 15% [13–17];
P = 0.0594), complete EVR (59% [46–72] vs 31% [28–34];
P < 0.0001), EVR (76% [63–86] vs 55% [52–59]; P = 0.0007),
ETR (69% [56–81] vs 35% [32–38]; P < 0.0001), and SVR rates
(46% [33–59] vs 16% [14–18]; P < 0.0001) were higher in patients
with non-cirrhotic than cirrhosis-related thrombocytopenia,
respectively.
Platelet count dynamics according to antiviral
treatment outcome. Figure 2a and b show the dynamics of
platelet count (median and interquartile range) during PEG-IFN
and RBV treatment according to FS test results in the eltrombopag
and placebo arms, respectively. The median platelet count tended
to be higher in patients with non-cirrhotic thrombocytopenia
throughout the course of antiviral treatment as compared with
cirrhosis-related thrombocytopenia in both the eltrombopag
(week 4: 128.0 × 109/L vs 94.5 × 109/L; week 12: 120.0 × 109/L
vs 96.0 × 109/L; week 24: 128.5 × 109/L vs 95.0 × 109/L; end of
treatment: 130.0 × 109/L vs 95.5 × 109/L) and placebo (week 4:
80.0 × 109/L vs 47.0 × 109/L; week 12: 113.5 × 109/L vs 44.0 ×
109/L; week 24: 100.1 × 109/L vs 43.0 × 109/L; end of treatment:
72.0 × 109/L vs 45.0 × 109/L) groups, although this trend was defi-
nitely more evident in the latter group of patients. Table 2 shows
that, when patients were further subdivided according to SVR, this
phenomenon was more marked in patients with non-cirrhotic
thrombocytopenia who obtained an SVR, especially in those
treated with placebo in whom the increase in platelet counts was
more evident due to the absence of the thrombopoietic effect of
eltrombopag (Fig. 3a–d).
Safety. Although the incidence of thromboembolic events was
similar in the two groups of patients (non-cirrhotic vs cirrhotic: 3%
[n = 2; 95% CI, 0–12] vs 3% [n = 26; 95% CI, 2–4], respectively),
the incidence of hepatic decompensation was lower in patients
with non-cirrhotic thrombocytopenia (2% [n = 1; 95% CI, 0–9] vs
12% [n = 116; 95% CI, 10–14], respectively).
Discussion
The present study demonstrates for the first time that a small
but significant population of patients with HCV infection and
thrombocytopenia has distinct clinical features and treatment
responses to interferon that differentiate them from patients with
cirrhosis.
Previous studies have shown a prevalence of antiplatelet anti-
bodies as high as 66% in patients with chronic HCV infection, but
without a correlation with platelet count, whereas other studies
have shown that clearance of HCV during interferon-based anti-
viral therapy was associated with increased platelet counts in some
patients.15,26,27 This evidence points to the possible existence,
Table 1 Baseline demographic, clinical, and virologic characteristics of patients subdivided according to non-cirrhotic and cirrhosis-related throm-
bocytopenia
Characteristic Non-cirrhotic (n = 59) Cirrhotic (n = 995) P-value
Age, mean, years (95% CI) 43.9 (40.7–47.2) 52.7 (52.2–53.3) < 0.0001
Female, n (%, 95% CI) 38 (64, 51–76) 295 (30, 27–33) < 0.0001
Body mass index, mean, kg/m2 (95% CI) 26.8 (25.4–28.2) 27.8 (27.5–28.0) 0.1359
Albumin ≤ 35 g/L, n (%, 95% CI) 1 (2, 0–9) 320 (32, 29–35) < 0.0001
Bilirubin, mean, μmol/L (95% CI) 13.53 (12.23–14.82) 23.63 (23.09–24.18) < 0.0001
Creatinine, mean, μmol/L (95% CI) 69.7 (66.3–73.1) 70.9 (70.1–71.8) 0.4947
INR, mean (95% CI) 1.18 (1.11–1.24) 1.24 (1.23–1.26) 0.0367
Platelet count, mean, ×109/L (95% CI) 56 (52–61) 57 (56–58) 0.7278
HCV genotypes 1, 4, and 6, n (%, 95% CI) 42 (71, 58–82) 687 (69, 66–72) 0.9581
HCV RNA, mean, ×106 IU/mL (95% CI) 2.03 (1.24–2.82) 1.55 (1.39–1.70) 0.1533
AST/ALT ratio > 0.8, n (%, 95% CI) 40 (68, 54–79) 895 (90, 88–92) < 0.0001
Diabetes mellitus, n (%, 95% CI) 2 (3, 0–12) 209 (21, 19–24) 0.0005
Child-Pugh class A, n (%, 95% CI) 58 (98, 91–100) 946 (95, 94–96) 0.2513
MELD score ≥ 10, n (%, 95% CI) 14 (24, 14–37) 452 (45, 42–49) 0.0012
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HCV, hepatitis C virus; INR, international normalized ratio;
MELD, Model for End-Stage Liver Disease.
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within the population of patients with HCV infection and throm-
bocytopenia, of heterogeneous subgroups of patients in which this
hematologic abnormality may be due to different mechanisms and
whose clinical characteristics and thrombocytopenic response to
antiviral therapy have not been thoroughly assessed.
The ENABLE-1 and ENABLE-2 studies were randomized,
double-blind, placebo-controlled studies that were performed in
order to evaluate the ability of eltrombopag to allow initiation and
maintenance of PEG-IFN and RBV therapy in a large series of
patients with chronic HCV infection in which thrombocytopenia
was the only limiting factor for antiviral treatment initiation.18 In
these studies, the majority of patients had advanced fibrosis or
cirrhosis according to FS test results.18–20,22 However, we observed
that approximately 5% of the study population had thrombocyto-
penia despite FS test results that were compatible with the pres-
ence of minimal or absent fibrosis, suggesting that decreased
platelet counts were associated neither with the presence of cir-
rhosis nor presumably with portal hypertension in these
patients.19,20,22
Despite using different methods for assessing disease stage, a
community-based study that evaluated the relationship between
severity of liver disease and thrombocytopenia in patients with
chronic HCV infection showed that 2.3–5.1% of patients with a
platelet count below 100 x109/L had ultrasonographic evidence of
“normal” or “fatty liver,”28 a prevalence quite similar to that
observed in the present study. In this study, we observed that
virologic characteristics (HCV viral load and genotype) were not
different in patients with non-cirrhotic and cirrhosis-related throm-
bocytopenia, although we found that patients with non-cirrhotic
thrombocytopenia were more frequently younger and female and
had clinical and biochemical features of less advanced liver
disease, such as a lower prevalence of a MELD score ≥ 10 and an
AST/ALT ratio > 0.8, as compared with patients with cirrhosis-
related thrombocytopenia. Previous reports of small series of
patients with chronic HCV infection and suspected immune
thrombocytopenia have also reported a higher prevalence in
women, a finding at odds with the commonly reported greater
incidence of HCV infection in men.15,16,29 In contrast, the preva-
lence of diabetes mellitus, which is considered to be among the
extrahepatic manifestations of HCV infection, was higher in
patients with cirrhosis-related thrombocytopenia, a finding consis-
tent with the higher prevalence of this metabolic disease in patients
with more advanced liver disease.30,31 Overall, these findings
suggest that chronic HCV infection may also induce thrombocy-
topenia in a subset of patients with preserved liver function and
less advanced disease. This phenomenon is more frequent in
women, while no association seems to be evident with viral load
and genotype.
We observed that response to antiviral therapy was improved in
patients with non-cirrhotic thrombocytopenia as compared with
patients with cirrhosis-related thrombocytopenia, with this differ-
ence definitely more evident from week 12 of treatment onward.
Despite patients’ similar baseline virologic characteristics, this
finding was likely because of a greater prevalence of unfavorable
characteristics (male sex, diabetes, decreased liver synthetic func-
tion, and higher MELD scores) in patients with cirrhosis-related
thrombocytopenia and to the inherent lower interferon sensitivity
of patients with more advanced liver disease.32,33 SVR rates with
PEG/RBV vary depending on HCV genotype and the presence of
liver fibrosis/cirrhosis, with patients infected with genotype 2 or 3
and non-cirrhotic patients achieving higher SVR rates.34–36 The
ENABLE population included patients infected with various HCV
genotypes, but mostly genotype 1, and most patients had cirrho-
sis.18 Lastly, the SVR rates observed in the current study in patients
without cirrhosis who had thrombocytopenia were not dissimilar
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Figure 1 Overall virologic responses in patients by FibroSURE test
results at the various treatment milestones in patients with (a) non-
cirrhotic and (b) cirrhosis-related thrombocytopenia. Data are shown as
percentage (95% confidence interval). cEVR, complete early virolo-
gic response; ETR, end-of-treatment response; EVR, early virologic
response; RVR, rapid virologic response; SVR, sustained virologic
response. Eltrombopag; Placebo.
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thrombocytopenia after 24 weeks of PEG/RBV (46.0% vs
49.4%).36 Although similar results were obtained for EVR (76.0%
vs 60.3–94.9% depending on genotype), RVR tended to be lower
in our study (22.0% vs 26.5–84.7% depending on genotype).36
However, it must be emphasized that, in non-cirrhotic patients, the
presence of severe thrombocytopenia prevented the beginning of
antiviral therapy and that pretreatment with eltrombopag enabled
these patients to start PEG-IFN and RBV treatment.18
Lastly, the most relevant result of this study is that, looking at the
longitudinal modifications of platelet counts during antiviral
therapy, it is evident that patients with non-cirrhotic thrombocyto-
penia tended to have a higher mean platelet count than that of
patients with cirrhosis-related thrombocytopenia. This finding
was even more evident in the placebo arm of the study, in which
patients with non-cirrhotic thrombocytopenia—despite some vari-
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Figure 2 Platelet counts during the antiviral treatment phase according to FibroSURE test results in patients treated with (a) eltrombopag and
(b) placebo subdivided according to FibroSURE test results (blue line, non-cirrhotic; green line, cirrhotic). Data are shown as median and interquartile
range. AVB, antiviral baseline; EOT, end of treatment; W, week. P < 0.001 for FibroSURE < 0.4 vs ≥ 0.75 based on post-hoc mixed model for repeated
measures (while on treatment) analysis of log platelet values with log baseline platelet, baseline FibroSURE subgroup, and FibroSURE subgroup by
visit interaction.
Table 2 Platelet counts during antiviral treatment and at follow-up subdivided according to treatment arm, FibroSURE test results, and response to
antiviral treatment
Placebo Eltrombopag
Non-cirrhotic Cirrhotic Non-cirrhotic Cirrhotic








Week 4 8 139.5 (99.5–178.5) 40 52.0 (41.5–73.5) 19 150.0 (87.0–178.0) 119 97.0 (74.0–144.0)
Week 12 8 139.1 (124.0–225.5) 40 45.0 (39.5–58.0) 18 125.5 (100.0–159.0) 119 104.0 (79.0–133.0)
Week 24 7 159.0 (97.1–200.0) 17 46.0 (37.0–51.0) 12 151.0 (114.5–212.0) 68 103.0 (74.0–124.5)
End of treatment 8 145.5 (103.7–226.5) 39 44.0 (33.0–59.0) 18 148.5 (105.0–162.0) 119 103.0 (76.0–137.0)
Week 24 follow-up 8 130.0 (88.0–211.0) 40 55.5 (48.0–79.0) 19 94.0 (64.0–172.0) 118 65.0 (50.0–87.0)








Week 4 17 52.0 (35.0–102.0) 269 46.0 (36.0–59.0) 14 117.5 (91.0–152.0) 517 94.0 (70.0–127.0)
Week 12 14 64.2 (39.0–149.0) 188 44.0 (36.0–58.0) 11 114.0 (73.0–217.0) 473 93.0 (69.0–119.0)
Week 24 9 78.0 (44.0–103.0) 105 43.0 (34.0–53.8) 6 85.0 (67.0–105.0) 277 93.0 (72.0–121.0)
End of treatment 16 50.0 (41.0–72.0) 272 45.0 (32.0–56.0) 15 120.0 (60.0–179.0) 491 94.0 (65.0–126.0)
Week 24 follow-up 13 57.0 (27.0–72.0) 233 55.0 (43.0–70.0) 12 58.5 (47.0–129.5) 424 58.0 (46.0–72.0)
IQR, interquartile range; SVR, sustained virologic response.
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from week 4 onward. Moreover, when placebo-treated patients
were subdivided according to antiviral treatment outcomes, we
found that the increase in platelet count during treatment was
observed mainly in non-cirrhotic patients who cleared HCV infec-
tion. These patients had a median platelet count consistently above
130–150 × 109/L throughout the duration of antiviral therapy and
also maintained elevated platelet counts at week 24 of follow-up.
These data suggest that, in patients with non-cirrhotic thrombocy-
topenia, successful antiviral treatment improves platelet counts
during and after treatment, raising the possibility that a virus-
mediated mechanism may be responsible for decreased platelet
count in these patients. The results corroborate previous anecdotal
evidence and results obtained in small series of patients.15,26
This study has a few limitations, besides being based on a
post-hoc analysis. There was no assessment of antiplatelet anti-
bodies, so it cannot be determined if antiplatelet antibodies were
more prevalent in patients with non-cirrhotic thrombocytopenia.
However, previous studies have shown a high prevalence of
antiplatelet antibodies in patients with HCV infection and no cor-
relation with platelet count.27 Another limitation of the study is
inherent in the definition of “non-cirrhotic” or “cirrhosis-related”
thrombocytopenia, which was based on the FS test results alone
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Figure 3 Platelet counts during antiviral therapy in patients subdivided according to treatment received and response to antiviral therapy (placebo
[(a) achieving SVR and (b) not achieving SVR]; eltrombopag [(c) achieving SVR and (d) not achieving SVR]) and FibroSURE test results (blue line,
non-cirrhotic; green line, cirrhotic). Data are shown as median and interquartile range. AVB, antiviral baseline; EOT, end of treatment; SVR, sustained
virologic response; W, week. P < 0.001 for FibroSURE < 0.4 vs ≥ 0.75 based on post-hoc mixed model for repeated measures (while on treatment)
analysis of log platelet values with log baseline platelet, baseline FibroSURE subgroup, and FibroSURE subgroup by visit interaction.
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because a liver biopsy was not required for enrollment into the
ENABLE studies.18 Indeed, FS has shown reliable accuracy for the
noninvasive diagnosis of cirrhosis,19–23 while it showed only
modest accuracy for the diagnosis of lower stage liver fibrosis in
patients with HCV infection.37 Thus, it is possible that some
patients with low FS test results might have been misclassified as
patients with non-cirrhotic thrombocytopenia when they actually
had cirrhosis-related thrombocytopenia. This possible limitation
of the study is further highlighted by the finding that 24% of
patients with non-cirrhotic thrombocytopenia had a MELD
score ≥ 10, a score rarely found in patients with mild liver disease.
In conclusion, the results of this study suggest the existence of
a small subset of patients with HCV infection and thrombocyto-
penia, who are predominantly young and female, in which this
hematologic abnormality is more frequently associated with fea-
tures of less advanced liver disease and in which viral clearance
may be associated with improvement in platelet counts.
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